我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 BAYER AG
相关临床试验
128
120 进行中
药物批准
20
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
118
92.2%
已完成
0.8%
尚未招募
2
1.6%
招募中
7
5.5%
SFDA
Saudi Food and Drug Authority
- BridgeBio Pharma secured $300 million in upfront financing by selling 60% of European royalties for BEYONTTRA to HealthCare Royalty and Blue Owl Capital. - The transaction monetizes royalties on the first $500 million of annual BEYONTTRA net sales in Europe with a 1.45x cap on total investor payments. - Acoramidis demonstrated rapid clinical benefits in Phase 3 trials, showing 42% reduction in cardiovascular events and 50% reduction in cardiovascular hospitalizations. - The drug is approved as Attruby in the US and BEYONTTRA in Europe for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
